Advances in Novel Drug Delivery Strategies for Breast Cancer Therapy

被引：89

作者：

Dhankhar, Ritu ^{[1
]}

Vyas, Suresh P. ^{[2
]}

Jain, Arvind K. ^{[1
]}

Arora, Sahil ^{[1
]}

Rath, Goutam ^{[1
]}

Goyal, Amit K. ^{[1
]}

机构：

[1] ISF Coll Pharm, Dept Pharmaceut, Nanomed Res Ctr, Moga 142001, Punjab, India

[2] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Drug Delivery Res Lab, Sagar, MP, India

来源：

ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY | 2010年 / 38卷 / 05期

关键词：

breast cancer; drug targeting; liposomes; nanoparticles; growth factor receptor; SOLID LIPID NANOPARTICLES; GROWTH-FACTOR RECEPTOR; ACTIVITY IN-VITRO; CELLULAR UPTAKE; MONOCLONAL-ANTIBODIES; COPOLYMER MICELLES; ANTITUMOR-ACTIVITY; CONTROLLED-RELEASE; INHIBITS BREAST; CELLS;

D O I：

10.3109/10731199.2010.494578

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Breast cancer remains one of the world's most devastating diseases. However, better understanding of tumor biology and improved diagnostic devices could lead to improved therapeutic outcomes. Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Various nanocarriers have been introduced to improve the therapeutic efficacy of anticancer drugs, including liposomes, polymeric micelles, quantum dots, nanoparticles, and dendrimers. Recently, targeted drug delivery systems for anti-tumor drugs have demonstrated great potential to lower cytotoxicity and increase therapeutic effects. Various ligands/approaches have been explored for targeting breast cancer. This paper provides an overview of breast cancer, conventional therapy, potential of nanotechnology in management of breast cancer, and rational approaches for targeting breast cancer.

引用

页码：230 / 249

页数：20

共 110 条

[1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].

Agus, DB ;

Akita, RW ;

Fox, WD ;

Lewis, GD ;

Higgins, B ;

Pisacane, PI ;

Lofgren, JA ;

Tindell, C ;

Evans, DP ;

Maiese, K ;

Scher, HI ;

Sliwkowski, MX .

CANCER CELL, 2002, 2 (02) :127-137

[2]

ALPER J, 2006, NCI ALLIANCE NANOTEC, P1

[3] The Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 Inhibits Aromatase [J].

Banerjee, Susana ;

Zvelebil, Marketa ;

Furet, Pascal ;

Mueller-Vieira, Ursula ;

Evans, Dean B. ;

Dowsett, Mitch ;

Martin, Lesley-Ann .

CANCER RESEARCH, 2009, 69 (11) :4716-4723

[4]

Baulida J, 1996, J BIOL CHEM, V271, P5251

[5]

Bellucci S, 2009, NANOMEDICINE-UK, V4, P531, DOI [10.2217/nnm.09.36, 10.2217/NNM.09.36]

[6] HER2/Neu: mechanisms of dimerization/oligomerization [J].

Brennan, PJ ;

Kumogai, T ;

Berezov, A ;

Murali, R ;

Greene, MI .

ONCOGENE, 2000, 19 (53) :6093-6101

[7] Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1 [J].

Caine, GJ ;

Blann, AD ;

Stonelake, PS ;

Ryan, P ;

Lip, GYH .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (10) :883-890

[8] Gastrin Releasing Protein Receptor Specific Gold Nanorods: Breast and Prostate Tumor Avid Nanovectors for Molecular Imaging [J].

Chanda, Nripen ;

Shukla, Ravi ;

Katti, Kattesh V. ;

Kannan, Raghuraman .

NANO LETTERS, 2009, 9 (05) :1798-1805

[9]

CHANG E, 2007, BIOTECHNOL J, V2, P2

[10]

Chen YC, 2003, CANCER RES, V63, P4801

← 1 2 3 4 5 6 7 8 9 10 →